GSK, Novartis And Teva COPD Drugs Breeze Through EMA Together
This article was originally published in The Pink Sheet Daily
Executive Summary
The EMA has recommended for authorization drugs from GSK, Novartis and Teva, setting the scene for a show-down in the increasingly competitive European COPD respiratory market.
You may also be interested in...
Breo Coverage Gaining Ground, GSK’s Witty Assures Investors
GlaxoSmithKline’s COPD drug Breo Ellipta is facing reimbursement challenges, particularly in terms of Medicare Part D coverage. But CEO Andrew Witty told investors during a year-end sales and earnings call Feb. 5 that coverage is increasing and will continue to grow through 2014.
FDA Approves GSK’s Anoro Ellipta, The First LABA/LAMA Combination
FDA approved GSK’s Anoro Ellipta as the first LABA/LAMA combination product in the U.S. for the maintenance treatment of COPD Dec. 18, positioning GSK to launch a second respiratory product months after launching Breo Ellipta.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.